Causal vaccine effects on binary postinfection outcomes

Journal of the American Statistical Association

Volumn 101, Issue 473, 2006, Pages 51-64

  Hudgens, Michael G ^a   Halloran, M Elizabeth ^b  

^a IL   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Causal inference; Infectious disease; Maximum likelihood; Principal stratification; Sensitivity analysis

Indexed keywords

EID: 33645505986     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1198/016214505000000970     Document Type: Article

References (42)

1. Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996), "Identification of Causal Effects Using Instrumental Variables," Journal of the American Statistical Association, 91, 444-455.
2. Balke, A., and Pearl, J. (1997), "Bounds on Treatment Effects From Studies With Imperfect Compliance," Journal of the American Statistical Association, 92, 1171-1176.
3. Barndorff-Nielsen, O. E., and Cox, D. R. (1994), Inference and Asymptotics, New York: Chapman & Hall.
4. Burke, D. S. (1992), "Human HIV Vaccine Trials: Does Antibody-Dependent Enhancement Pose a Genuine Risk?" Perspectives in Biology and Medicine, 35, 511-530.
5. Clements-Mann, M. L. (1998), "Lessons for AIDS Vaccine Development From Non-AIDS Vaccines," AIDS Research and Human Retroviruses, 14 (Suppl. 3), S197-203.
6. Cox, D. R. (1958), Planning of Experiments, New York: Wiley.
7. Fletcher, R. (1987), Practical Methods of Optimization, New York: Wiley.
8. Frangakis, C. E., and Rubin, D. B. (2002), "Principal Stratification in Causal Inference," Biometrics, 58, 21-29.
9. Gilbert, P. B., Bosch, R., and Hudgens, M. G. (2003a), "Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials," Biometrics, 59, 531-541.
10. Gilbert, P. B., DeGruttola, V., Hudgens, M. G., Self, S. G., Hammer, S. M., and Corey, L. (2003b), "What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine That Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 Trials," Journal of Infectious Diseases, 188, 179-193.
11. Halloran, M. E., Préziosi, M.-P., and Chu, H. (2003), "Estimating Vaccine Efficacy From Secondary Attack Rates," Journal of the American Statistical Association, 98, 38-46.
12. Halloran, M. E., and Struchiner, C. J. (1995), "Causal Inference in Infectious Diseases," Epidemiology, 6, 142-151.
13. Halloran, M. E., Struchiner, C. J., and Longini, I. M. (1997), "Study Designs for Evaluating Different Efficacy and Effectiveness Aspects of Vaccines," American Journal of Epidemiology, 146, 789-803.
14. Hayes, R. J., Alexander, N. D. E., Bennett, S., and Consens, S. N. (2000), "Design and Analysis Issues in Cluster-Randomized Trials of Interventions Against Infectious Diseases," Statistical Methods in Medical Research, 9, 95-116.
15. Holland, P. W. (1986), "Statistics and Causal Inference," Journal of the American Statistical Association, 81, 945-960.
16. Hudgens, M. G., Hoering, A., and Self, S. G. (2003), "On the Analysis of Viral Load Endpoints in HIV Vaccine Trials," Statistics in Medicine, 22, 2281-2298.
17. Imbens, G. W., and Rubin, D. B. (1997), "Bayesian Inference for Causal Effects in Randomized Experiments With Noncompliance," The Annals of Statistics, 25, 305-327.
18. Joe, H. (1997), Multivariate Models and Dependence Concepts, London: Chapman & Hall.
19. Kendrick, P., and Eldering, G. (1939), "A Study in Active Immunization Against Pertussis," American Journal of Hygiene, Sect. B, 38, 133.
20. Kliks, S. C., Nisalak, A., Brandt, W. E., Wahl, L., and Burke, D. S. (1989), "Antibody-Dependent Enhancement of Dengue Virus Growth in Human Monocytes as a Risk Factor for Dengue Hemorrhagic Fever," American Journal of Tropical Medicine and Hygiene, 40, 444-451.
21. Longini, I. M., Datta, S., and Halloran, M. E. (1996), "Measuring Vaccine Efficacy for Both Susceptibility to Infection and Reduction in Infectiousness for Prophylactic HIV-1 Vaccines," Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13, 440-447.
22. Manski, C. F. (1990), "Nonparametric Bounds on Treatment Effects," American Economic Review, Papers and Proceedings, 80, 319-323.
23. Mascola, J. R., Mathieson, B. J., Zack, P. M., Walker, M. C., Halstead, S. B., and Burke, D. S. (1993), "Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials," AIDS Research and Human Retroviruses, 9, 1175-1184.
24. McMichael, A., Mwau, M., and Hanke, T. (2002), "Design and Tests of an HIV Vaccine," British Medical Bulletin, 62, 87-98.
25. Mehrotra, D. V., Li, X., and Gilbert, P. B. (2005), "Dual-Endpoint Evaluation of Vaccine Efficacy: Application to a Proof-of-Concept Clinical Trial of a Cell-Mediated Immunity-Based HIV Vaccine," BARDS Technical Report 111, Merck Research Laboratories.
26. Molenberghs, G., Kenward, M. G., and Goetghebeur, E. (2001), "Sensitivity Analysis for Incomplete Contingency Tables: The Slovenian Plebiscite Case," Applied Statistics, 50, 15-29.
27. Nabel, G. J. (2001), "Challenges and Opportunities for Development of an AIDS Vaccine," Nature, 410, 1002-1007.
28. Préziosi, M.-P., and Halloran, M. E. (2003a), "Effects of Pertussis Vaccination on Transmission: Vaccine Efficacy for Infectiousness, " Vaccine, 21, 1853-1861.
29. _ (2003b), "Effects of Pertussis Vaccination on Severity: Vaccine Efficacy for Clinical Severity," Clinical Infectious Diseases, 37, 772-779.
30. Robins, J. M., and Greenland, S. (1992), "Identifiability and Exchangeability for Direct and Indirect Effects," Epidemiology, 3, 143-155.
31. _ (1994), "Adjusting for Differential Rates of Prophylaxis Therapy for PCP in High- versus Low-Dose AZT Treatment Arms in an AIDS Randomized Trial," Journal of the American Statistical Association, 89, 737-749.
32. Robins, J. M., Rotnitzky, A., and Scharfstein, D. O. (2000), "Sensitivity Analysis for Selection Bias and Unmeasured Confounding in Missing Data and Causal Inference Models," in Statistics in Epidemiology, Environment and Clinical Trials, eds. M. E. Halloran and D. A. Berry, New York: Springer-Verlag, pp. 1-94.
33. Rosenbaum, P. R. (1984), "The Consequences of Adjustment for a Concomitant Variable That Has Been Affected by the Treatment," Journal of the Royal Statistical Society, Ser. A, 147, 656-666.
34. _ (1995), Observational Studies, Berlin: Springer-Verlag.
35. Rubin, D. B. (1978), "Bayesian Inference for Causal Effects: The Role of Randomization," The Annals of Statistics, 6, 34-58.
36. _ (1990a), "Comment: Neyman (1923) and Causal Inference in Experiments and Observations Studies," Statistical Science, 5, 472-480.
37. _ (1990b), "Formal Modes of Statistical Inference for Causal Effects," Journal of Statistical Planning and Inference, 25, 279-292.
38. _ (2000), Comment on "Causal Inference Without Counterfactuals, " by A. P. Dawid, Journal of the American Statistical Association, 95, 435-437.
39. Scharfstein, D. O., Rotnitzky, A., and Robins, J. M. (1999), "Adjusting for Non-ignorable Drop-Out Using Semiparametric Nonresponse Models," Journal of the American Statistical Association, 94, 1096-1146.
40. Struchiner, C. J., and Halloran, M. E. (1996), "Randomization and Baseline Transmission in Vaccine Field Trials," technical report, Emory University, Dept. of Biostatistics.
41. Vazquez, M., LaRussa, P. S., Gershon, A. A., Steinberg, S. P., Freudigman, K., and Shapiro, E. D. (2001), "The Effectiveness of the Varicella Vaccine in Clincial Practice," New England Journal of Medicine, 344, 955-960.
42. Vesikari, T., Rautanen, T., Varis, T., Beards, G. M., and Kapikian, A. Z. (1990), "Rhesus Rotavirus Candidate Vaccine: Clinical Trial in Children Vaccinated Between 2 and 5 Months of Age," American Journal of Diseases of Children, 144, 285-289.